Atlas Trials

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Clinical trial NCT02450903 · COMPLETED

Trial details

NCT number
NCT02450903
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Small-Cell Lung Cancer
Start date
2015-08-21
Primary completion
2017-07-31
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.